For research and educational purposes only. Not medical advice.
Urolithin A Reference
Educational, not medical advice reference for Urolithin A: Longevity; regulatory status, evidence posture, source review, and schedule notes. Also known as U…
Reference summary
Andreux 2019 Nat Metab reported safety and a molecular signature of improved mitochondrial health in humans. Singh 2022 Cell Rep Med (middle-aged adults) and Liu 2022 JAMA Network Open (older adults) reported improvements in muscle endurance and mitochondrial biomarkers in randomized trials. All published human data are surrogate-marker; no Phase 3 outcome trial exists.
Regulatory and posture
- Categories
- Longevity
- Aliases
- UA, Mitopure (Amazentis brand), Ellagitannin metabolite (OTC dietary supplement)
- Evidence posture
- human - Surrogate-marker human RCTs only; no outcome trial.
- Regulatory status
- Over-the-counter dietary supplement in the United States. Urolithin A from Amazentis (sold under the Mitopure brand) received an FDA GRAS 'no questions' letter in December 2018 (GRN 791); GRAS designates safe-as-food, not approved-as-drug. Not FDA-approved as a drug for any indication.
- Content review status
- research reference
Selected public sources
- PubMed: Andreux et al. Nat Metab 2019 - urolithin A is safe and induces a molecular signature of improved mitochondrial health in humans (PMID 32694802)
- PubMed: Singh et al. Cell Rep Med 2022 - urolithin A improves muscle strength and exercise performance in middle-aged adults RCT (PMID 35584623)
- PubMed: Liu et al. JAMA Netw Open 2022 - urolithin A supplementation on muscle endurance and mitochondrial health in older adults RCT (PMID 35050355)